Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$-0.10
EPS est.
$-0.14
EPS surprise
+28.57%
1-day move
+1.89%
Travere Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 1.89%. However, the lack of revenue figures and management commentary leaves uncertainty about the company's overall performance and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | +28.57% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Travere Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. With a market cap of $6 billion, it plays a crucial role in addressing unmet medical needs in the healthcare sector.
Last quarter
In Q1 2026, Travere reported an EPS of $0.05, significantly beating expectations by 116.78%. The stock reacted positively, gaining 1.79% the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+253.84%
Avg 1-day reaction
+1.31%
Investors are cautiously optimistic ahead of the earnings report, given the company's strong recent performance and history of beating EPS estimates.
Bull case
If Travere continues its trend of positive surprises, it could lead to increased investor confidence and a significant stock price increase.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
Given Travere's history of beating EPS estimates, this figure will be crucial for market sentiment.
Q2
What guidance will management provide for future revenue growth?
Future revenue guidance will be key in assessing the company's growth trajectory and investor confidence.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate Travere's ability to sustain its recent performance, as historical trends show a consistent pattern of positive surprises.
Supporting evidence
The company has a 100% EPS beat rate over the last four quarters.
Options are pricing a 20% move, which is significantly higher than the historical average of 2.16%.
Key risk
If EPS comes in above $0.10, it could challenge the cautious sentiment and drive the stock higher.
Pre-commit to what would confirm each case.
The market is weighing the potential for continued profitability against the risks of unmet expectations.
Bull confirmed if
An EPS of $0.10 or higher would confirm the bull case.
Bear confirmed if
An EPS below $0.00 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±20.03%
Historical Avg
±2.0%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±20.0% while TVTX has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
43.7%
Smart-money positioning from the most recent 13F filings.
Institutional
115.16%
of float
Insider
0.69%
of float
Holders
437
institutions
Top Holders· as of Jun 2026
Jupiter Topco LLC
11,324,191 sh · $605.2M
12.01%
100.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Travere beats expectations, history suggests the stock could rise by around 0.68%, confirming the bullish sentiment.
In line / cautious
If results are in line but management is cautious, the stock may experience minimal movement as investors reassess their outlook.
Miss
If the company misses expectations, the stock could drop, with historical data suggesting a potential decline of around 2.16%.
The lines on the call that would change the story.
Blackrock Inc.
8,020,663 sh · $428.6M
8.51%
2.9%
FMR, LLC
7,096,614 sh · $379.2M
7.53%
-35.3%
Bank of America Corporation
4,568,341 sh · $244.1M
4.85%
239.6%
State Street Corporation
4,256,224 sh · $227.5M
4.52%
-14.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.